‘The Best Decision I Ever Made’: Wolfgang Miesbach Marks 10 Years Since First Haemophilia B Gene Therapy Trial at Frankfurt
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X:
“The Best Decision I Ever Made – Celebrating 10 Years of Gene Therapy at Frankfurt University Hospital. 10 years ago today, on July 22, 2015, Frankfurt University Hospital set a groundbreaking milestone by enrolling the first participant in the AMT-060 gene therapy trial for haemophilia B. This trial introduced an AAV5 vector carrying the wild-type Factor IX gene.
This would not have been possible without the outstanding expertise and close cooperation with the DRK Blood Donor Services and the Institute for Transfusion Medicine in Frankfurt.
AMT-060 was initiated during an early stage marked by scientific uncertainty. Long-term efficacy, safety, and side effect management were still largely unknown. Progress became possible through remarkable collaboration among researchers across the Netherlands, Denmark, Germany, and Italy. This multinational team—including leading hepatologists—leveraged a hub-and-spoke model to ensure treatment of patients from diverse centers and maintain seamless communication.
Over the past decade, scientific progress has been remarkable. The successor therapy, Etranacogene dezaparvovec (AMT-061), which utilizes the same AAV5 capsid combined with the hyperactive Padua variant of Factor IX, has received regulatory approval—a milestone that underscores the transition from early uncertainty to the availability of established gene therapy options for haemophilia.
Today, those early trial participants continue to benefit from sustained improvements, demonstrating the real-world impact of clinical innovation. During a recent follow-up, one patient expressed: ‘This was the best decision I ever made.’
Deepest gratitude goes to all the investigators, patients, and industry partners—uniQure and CSL Behring—whose dedication made this development possible.”
Wolfgang Miesbach reflects on the 10-year journey of gene therapy for haemophilia B at Frankfurt University Hospital, celebrating the groundbreaking AMT-060 trial, its collaborative success, and its lasting impact on patients.
Stay updated with Hemostasis Today.
-
Jul 22, 2025, 17:19Wolfgang Miesbach Shares Newly Released Gene Therapy Qualification Criteria Paper
-
Jul 22, 2025, 17:05EAHAD Launches Europe-Wide Survey on Haemophilia Gene Therapy Readiness
-
Jul 22, 2025, 09:26Hemophilia of Georgia Highlights Participation in WFH 2025 Summit and Global Youth Training
-
Jul 22, 2025, 08:55tPA in Action: Quick‑Guide to Alteplase Dosage for Common Thrombotic Emergencies
-
Jul 22, 2025, 08:37Georgina Santiapillai Wins 2025 BSH Crucible Prize
-
Jul 22, 2025, 09:17Decoding Antiphospholipid Syndrome: Why Triple Positivity Is a Red Flag for Thrombosis
-
Jul 21, 2025, 16:24Code I26: A Precise Tool to Strengthen VTE Surveillance
-
Jul 20, 2025, 17:12Thromboelastography: Coagulation Beyond INR and aPTT
-
Jul 20, 2025, 16:555 Crucial Insights into Low VWF QL: Uncovering a Distinct Cause of Bleeding
-
Jul 19, 2025, 17:16Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 22, 2025, 16:48How Children See Blood Clots: World Thrombosis Day Shares Artwork from Young Artists
-
Jul 22, 2025, 08:48NBCA: From Marathon Dreams to ICU — Sam’s Blood Clot Wake-Up Call
-
Jul 21, 2025, 13:10What’s Slowing Down Gene Therapy Uptake in Hemophilia? Brian O’Mahony Explains the Real-World Barriers
-
Jul 20, 2025, 17:17Michael Makris Shares 2 Fascinating Lessons from Hemophilia Care in Japan
-
Jul 16, 2025, 10:24Salma Ismail: Honored to Be Invited By the EHA2025 as Part of Their Lighting the Flame Program